JP2018533557A5 - - Google Patents

Download PDF

Info

Publication number
JP2018533557A5
JP2018533557A5 JP2018517626A JP2018517626A JP2018533557A5 JP 2018533557 A5 JP2018533557 A5 JP 2018533557A5 JP 2018517626 A JP2018517626 A JP 2018517626A JP 2018517626 A JP2018517626 A JP 2018517626A JP 2018533557 A5 JP2018533557 A5 JP 2018533557A5
Authority
JP
Japan
Prior art keywords
antagonist
group
calcitonin
antibody
disorder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018517626A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018533557A (ja
JP6858182B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/055502 external-priority patent/WO2017062456A2/en
Publication of JP2018533557A publication Critical patent/JP2018533557A/ja
Publication of JP2018533557A5 publication Critical patent/JP2018533557A5/ja
Application granted granted Critical
Publication of JP6858182B2 publication Critical patent/JP6858182B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018517626A 2015-10-06 2016-10-05 インターロイキン33(il−33)媒介疾患に関するバイオマーカーおよびその使用 Active JP6858182B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562237624P 2015-10-06 2015-10-06
US62/237,624 2015-10-06
PCT/US2016/055502 WO2017062456A2 (en) 2015-10-06 2016-10-05 Biomarkers related to interleukin-33 (il-33)-mediated diseases and uses thereof

Publications (3)

Publication Number Publication Date
JP2018533557A JP2018533557A (ja) 2018-11-15
JP2018533557A5 true JP2018533557A5 (enExample) 2019-11-14
JP6858182B2 JP6858182B2 (ja) 2021-04-14

Family

ID=57223756

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018517626A Active JP6858182B2 (ja) 2015-10-06 2016-10-05 インターロイキン33(il−33)媒介疾患に関するバイオマーカーおよびその使用

Country Status (12)

Country Link
US (2) US10005834B2 (enExample)
EP (1) EP3359567A2 (enExample)
JP (1) JP6858182B2 (enExample)
KR (1) KR102687412B1 (enExample)
CN (1) CN108137682B (enExample)
AU (1) AU2016333903B2 (enExample)
CA (1) CA3000725A1 (enExample)
EA (1) EA201890891A1 (enExample)
HK (2) HK1259386A1 (enExample)
MA (1) MA50638A (enExample)
MX (1) MX2018004170A (enExample)
WO (1) WO2017062456A2 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3088517B1 (en) 2013-12-26 2023-11-01 Mitsubishi Tanabe Pharma Corporation Human anti-il-33 neutralizing monoclonal antibody
ES2866935T3 (es) 2014-01-10 2021-10-20 Anaptysbio Inc Anticuerpos dirigidos contra interleucina-33 (IL-33)
CR20170240A (es) 2014-11-10 2018-04-03 Genentech Inc Anticuerpos anti-interleucina-33 y sus usos
JP7231326B2 (ja) 2014-11-10 2023-03-01 ジェネンテック, インコーポレイテッド Il-33媒介性障害のための治療及び診断方法
EA201890891A1 (ru) 2015-10-06 2018-09-28 Ридженерон Фармасьютикалз, Инк. Биомаркеры, связанные с заболеваниями, опосредованными интерлейкином-33 (ил-33), и их применение
MX2018013038A (es) 2016-04-27 2019-03-28 Pfizer Anticuerpos anti-il-33, composiciones, metodos y usos de los mismos.
JP6871948B2 (ja) 2016-04-27 2021-05-19 アッヴィ・インコーポレイテッド 抗il−13抗体を使用する、il−13活性が有害である疾患の治療方法
MX2019012171A (es) * 2017-04-13 2019-11-25 Regeneron Pharma Tratamiento e inhibicion de enfermedades pulmonares inflamatorias en pacientes que tienen alelos de riesgo en los genes que codifican la il33 e il1rl1.
CA3066918A1 (en) 2017-06-12 2018-12-20 Bluefin Biomedicine, Inc. Anti-il1rap antibodies and antibody drug conjugates
IL272864B2 (en) * 2017-08-31 2024-03-01 Mitsubishi Tanabe Pharma Corp Il-33 antagonist-containing therapeutic agent for endometriosis
CN109061139A (zh) * 2018-06-19 2018-12-21 温州医科大学附属第医院 血清炎性生物标志物在防治急性缺血性脑梗死中的应用
TW202519263A (zh) 2019-03-21 2025-05-16 美商再生元醫藥公司 含有抗il-33抗體之穩定調配物
US20230099101A1 (en) * 2020-03-06 2023-03-30 The Regents Of The University Of Michigan Serine protease inhibitors for suppressing or preventing anaphylactic reaction
PE20230252A1 (es) 2020-03-13 2023-02-07 Genentech Inc Anticuerpos anti-interleucina-33 y sus usos de estos
JP7578943B2 (ja) * 2020-07-13 2024-11-07 学校法人自治医科大学 褥瘡治療剤
CN114814242B (zh) * 2022-06-10 2025-04-01 中日友好医院(中日友好临床医学研究所) 一种诊断慢性阻塞性肺疾病患者肌肉减少症的血液学标志物
EP4658247A1 (en) * 2023-01-31 2025-12-10 Vivacelle Bio, Inc. Compositions and methods for treating hyperprocalcitonemia
KR102834740B1 (ko) * 2023-04-10 2025-07-17 아주대학교산학협력단 Hsp10 또는 이의 항체를 유효성분으로 포함하는 만성 자발적 두드러기의 진단을 위한 바이오마커 조성물
WO2026007411A1 (zh) * 2025-02-11 2026-01-08 广州医科大学 抗IL1RL1/IL-33/NF-kB抗体和使用其治疗急性髓性白血病的方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4227454C1 (de) * 1992-08-19 1994-02-03 Henning Berlin Gmbh Verfahren zur Früherkennung, zur Erkennung des Schweregrads sowie zur therapiebegleitenden Verlaufsbeurteilung einer Sepsis sowie Mittel zur Durchführung des Verfahrens
NZ549040A (en) * 2004-02-17 2009-07-31 Schering Corp Use for interleukin-33 (IL33) and the IL-33 receptor complex
WO2010025393A2 (en) * 2008-08-28 2010-03-04 The Regents Of The University Of California Protein biomarkers and methods for diagnosing kawasaki disease
JO3532B1 (ar) * 2013-03-13 2020-07-05 Regeneron Pharma الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها
EP2968454B1 (en) 2013-03-15 2019-02-13 Regeneron Pharmaceuticals, Inc. Il-33 antagonists and uses thereof
AR098155A1 (es) * 2013-10-23 2016-05-04 Genentech Inc Métodos para diagnosticar y tratar trastornos eosinofílicos
EA201890891A1 (ru) 2015-10-06 2018-09-28 Ридженерон Фармасьютикалз, Инк. Биомаркеры, связанные с заболеваниями, опосредованными интерлейкином-33 (ил-33), и их применение

Similar Documents

Publication Publication Date Title
JP2018533557A5 (enExample)
Fulkerson et al. Targeting eosinophils in allergy, inflammation and beyond
JP2020513404A5 (enExample)
CN110167963B (zh) 治疗发炎病况的方法
Izuhara et al. IL-4 and IL-13: their pathological roles in allergic diseases and their potential in developing new therapies
RU2731713C2 (ru) Применение il-18-связывающего белка (il-18bp) при воспалительных заболеваниях
JP6858182B2 (ja) インターロイキン33(il−33)媒介疾患に関するバイオマーカーおよびその使用
JP2016536332A5 (enExample)
RU2016134838A (ru) Дипептидил пептидаза-4 (dpp4/cd26) как периферический биомаркер активации il-13 в астматическом легком
Grainge et al. Targeted therapeutics for severe refractory asthma: monoclonal antibodies
Hernandez‐Santana et al. Current perspectives on the interleukin‐1 family as targets for inflammatory disease
JP2017509692A5 (enExample)
JP2008502366A5 (enExample)
JP2013047259A (ja) Il−31アンタゴニストを用いて神経組織における疼痛及び炎症を治療する方法
HUE034005T2 (en) Therapies for improving lung function
JP2016529232A (ja) サイトカインアンタゴニストの標的化
RU2009120202A (ru) Способы и композиции для лечения и мониторинга лечения связанных с il-13 расстройств
EP3102601B1 (en) Novel assay to detect human periostin
KR20240049348A (ko) 항-인터루킨-33 항체를 사용한 만성 폐쇄성 폐질환의 치료
Mitchell et al. Anti-IgE and biologic approaches for the treatment of asthma
TWI870471B (zh) 全身性硬化症治療用醫藥組合物
EP4577570A1 (en) Treatment of asthma with an anti-interleukin-33 antibody
CN108135913A (zh) 治疗和/或预防特应性皮炎的il-17c拮抗剂
Syabbalo Clinical Features and Management of Eosinophilic Asthma
CN117264053B (zh) 白介素-9的抗体及其用途